Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public ...

Aug 17 (Reuters) - Fulcrum Therapeutics said on Monday it would merge with privately held Slate Medicines in an all-stock ...

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead ...

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of ...

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the ...

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therape ...

Blood disorder specialist Fulcrum Therapeutics has agreed to what amounts to a reverse merger with Slate Medicines, a ...

Cambridge biotech Fulcrum Therapeutics will complete a reverse merge with North Carolina-based Slate Medicines and pay ...

Fulcrum Therapeutics is merging with Slate Medicines in an all-stock deal, with the combined company set to operate under the Slate moniker and with a focus on Slate's portfolio of migraine treatments ...

Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to advance next-gen migraine therapies, backed by $245M financing.